Termination of Supply. (a) In the event Party B is unable to obtain conveniently certain services provided by Party A from any third party (including but not limited to any third party affiliated to Party A) and Party B notifies Party A of such situation from time to time, unless permitted by Party B in writing, Party A shall not terminate the supply of such services (other than for any breach of the provisions of this Agreement by Party B).
(b) Any party to the product and service implementation agreements (this Agreement excluded) entered into according to this Agreement may issue, in compliance with the Article 6.1(a) and 6.1(c), a written notice to the other to terminate the provision of products or services not less than six months in advance. Such notice shall stipulate what products or services will cease to be supplied and when such termination will take effect. If the supply of certain products or services is terminated according to this article, such termination shall neither affect other rights or obligations of Party A or Party B under this Agreement, nor affect other rights or obligations of any party to the product and service implementation agreements entered into according to this Agreement.
(c) If either party has issued a notice terminating the supply of certain services according to 6.1(b) hereof, unless otherwise agreed by both parties, such notice shall not terminate or affect the supply of such services agreed by both parties at the time of or prior to issuing such notice.
Termination of Supply. If NPC desires to terminate the supply of Products and/or Drug Substance to UPI in accordance with this Agreement and the Supply Agreement, then NPC shall give UPI [***] written notice of termination if before the First UPI Approval in any major market country of the UPI Territory and [***] written notice of termination if after the First UPI Approval in any major market country of the UPI Territory. During the notice period, NPC must use Commercially Reasonable Efforts to supply the reasonable orders expected to maintain the successful development and commercialization of the Products. Upon the termination of the supply of Products and/or Drug Substance by NPC to UPI, NPC will then use Commercially Reasonable Efforts to obtain and provide to UPI, in a timely fashion, batch records, assays methods and manufacturing details required and customary for the technical transfer of production activities for Products and/or Drug Substance to a new facility of UPI’s choice (with respect to such records, methods and details held or owned by a Third Party only to the extent that NPC is permitted to do so in writing by such Third Party), such that such UPI’s new facility may be validated and activated for production of Products and/or Drug Substance. If UPI desires to terminate the supply from NPC of Products and/or Drug Substance in accordance with this Agreement and the Supply Agreement, UPI must give NPC [***] written notice of termination if before the First UPI Approval in any major market country of the UPI Territory and [***] written notice of termination if after the First UPI Approval in any major market country of the UPI Territory. NPC will provide sufficient technical information in a timely fashion to allow the institution of production of Products and/or Drug Substance at a new UPI manufacturing location at UPI’s expense (with respect to such information held or owned by a Third Party only to the extent that NPC is permitted to do so in writing by such Third Party).
Termination of Supply. Abboxx xxx terminate this Agreement upon sixty (60) days written notice to Corixa following Abboxx'x xxxeipt of notice from Corixa or the Third Party Manufacturer given pursuant to Section 10.5.
Termination of Supply. The obligations of Fovea under this Section 6.2 to supply Finished Product to Dyax may be terminated by Fovea by giving written notice to Dyax that Fovea is terminating such obligations under this Section 6.2, in which case such obligations of Fovea shall terminate on the earlier of (i) the date on which Dyax and/or its Related Parties have established an alternative source of supply of Finished Product that can replace, without material interruption or delay, Fovea’s supply of Finished Product pursuant to this Section 6.2 and (ii) the [*****] that Fovea gives written notice of termination to Dyax pursuant to the foregoing provisions of this Section 6.2(e); provided, however, that, notwithstanding the foregoing, in no event shall Fovea’s obligations under Section 6.2(a) or (b) to supply Finished Product to Dyax terminate unless and until Fovea and all of its Related Parties have discontinued all Manufacturing of Finished Product. In the event that, at any time during the period in which Fovea has an obligation to supply Finished Product to Dyax pursuant to Section 6.2(a) or (b) above, Fovea is unable to supply or have supplied sufficient quantities of Finished Product to meet the reasonable requirements of Dyax and its Related Parties for use thereof in connection with the purposes and activities set forth in Section 6.2(a) or (b), as applicable, as indicated in good faith forecasts to be provided by Dyax pursuant to the Fovea Supply Agreement or this Section 6.2, then Dyax * Confidential Treatment Requested. Omitted portions filed with the Commission. shall have the right (but not the obligation) to Manufacture Finished Product solely for such purposes and activities. Dyax may exercise its rights under this Section 6.2(e) with respect to Finished Product by giving thirty (30) days prior written notice to Fovea. Dyax may also exercise its rights under this Section 6.2(e) upon the effective date of any termination by Fovea of its supply obligations as provided above. The exercise by Dyax of any of its rights under this Section 6.2(e) shall not relieve Fovea of its supply obligations under this Section 6.2. Upon receipt by Fovea of written notice from Dyax to the effect that Dyax is exercising its rights under this Section 6.2(e), Fovea shall provide reasonable assistance, at Dyax’s expense, to enable Dyax to Manufacture or have Manufactured Finished Product. [*****]
Termination of Supply. In the event Neurocrine elects to terminate the commitment to supply Clinical Drug Product or bulk Indiplon API for Commercialization pursuant to Sections 6.2 and 6.3 or DSP elects to Manufacture the Clinical Drug Product or bulk Indiplon API for Commercialization pursuant to Section 6.3, Neurocrine and DSP will in good faith prepare and agree on a schedule and plan pursuant to which DSP (directly or through contract manufacturers) can assume manufacturing responsibility at the first reasonable opportunity taking into consideration the avoidance of adverse impact such as delay of development schedule to the DSP Development Program. Neurocrine shall use best reasonable efforts to assist DSP in negotiating contracts with Neurocrine’s contract manufacturers with the goal of achieving terms and conditions as favorable to DSP as those Neurocrine has negotiated on its own behalf. Notwithstanding Neurocrine’s efforts in this regard, DSP acknowledges that manufacturing and supply terms are dependant upon a number of factors including number of products, volume and the like and there can be no assurance that contracts with Neurocrine’s contract manufacturers shall be available to DSP on terms equivalent to those provided to Neurocrine or at all.
Termination of Supply. In the event PeroxyChem decides to terminate its manufacture of the API and/or shut down its Facility that manufactures the API for Aclaris hereunder, PeroxyChem shall promptly provide Aclaris with written notice thereof, but in no event later than five (5) Business Days after having knowledge of making such decision. In the event that PeroxyChem shall make such decision to terminate its manufacture of API PeroxyChem shall take all actions as are necessary to ensure that it can provide Aclaris’ requirements for the API during the period in which Aclaris seeks approval from the FDA to use the API supplied by a Third Party. In the event that PeroxyChem is unable to provide Aclaris’ requirements in accordance with Section 2.2 hereof during the Term or such period, PeroxyChem shall reimburse Aclaris for (i) an amount equal to the factor obtained by multiplying the amount of replacement units of API procured by Aclaris from a Third Party(ies) as a result of PeroxyChem’s inability to supply such requirements during the Term or such period, by the difference, if any, between the per unit amount paid by Aclaris to such Third Party(ies) to procure such replacement API and the Purchase Price. For the avoidance of doubt, the Parties agree that the per unit amount paid by Aclaris to such Third Party (ies) shall be an arms-length, fair market value price.
Termination of Supply. Upon determination by INTERCARDIA or OPOCRIN that manufacture of the Licensed Compound cannot be manufactured within the reference parameters and provisions of this Article VIII, either party may terminate the supply and manufacturing provisions of this Agreement, and OPOCRIN shall transfer to INTERCARDIA all information relevant to the manufacture of the Licensed Compound.
Termination of Supply. As part of the process, notice of termination of supply must be provided to the Commissioning Supplier by the Customer or the Preferred Gas Supplier at least 15 days prior to the proposed effective date.
Termination of Supply. 17.1 Upon receipt of 14 days’ notice from the Resident the Company will terminate the supply of water at its stopcock. The Resident will remain liable for all sums due to the Company until such notice has expired even if he vacates the Premises before that date. Where it is not practicable to turn off the supply at the Company’s stopcock the Resident shall be responsible for any works to the service pipe which are needed to isolate the Premises from the Water main supply and the Resident shall be liable for all Charges until these works are completed to the satisfaction of the Company. On termination of the supply of water the Company shall be permitted to remove the meter and any other property of the Company and the Resident shall pay all costs thereon to the Company.
17.2 The Company shall have a right, without giving any reasons, to terminate the supply of water to any Resident upon giving the Resident 30 days’ notice.
17.3 On termination of the supply of water, the Company shall repay to the Resident any sum held on deposit under clause 4.6 after deducting any sums due to the Company.
17.4 The termination of the supply of water under this clause shall not affect the other provisions of this Agreement.
Termination of Supply. At or before the Effective Date, Infineon will give notice under the respective contracts that terminates the purchaser’s ability to acquire parts listed on s Schedules 1.21 or 1.10, in accordance with the requirements of the particular contract. The notice will refer those parties to TriQuint for inquiries regarding further supply, and copies will be provided to TriQuint as they are sent.
